Navigation Links
Risperdal Lawsuit News: Rottenstein Law Group LLP Comments on $2 Billion Risperdal Settlement Report
Date:11/8/2013

(PRWEB) November 08, 2013

Drug maker Johnson & Johnson has agreed to pay $2.2 billion in civil and criminal fines to settle claims it improperly marketed the antipsychotic medication Risperdal to children, seniors and people with developmental disabilities. The Rottenstein Law Group LLP, which represents clients in Risperdal lawsuits, notes that the federal government has reported that there are health risks associated with use of the drug among those groups.

The United States Department of Justice announced the settlement, which also includes heart-failure drug Natrecor and the antipsychotic Invega, according to a Nov. 4 New York Times story.* The federal government alleges J&J marketed the drug to high-risk groups between 1999 and 2005, the story said, adding that part of the settlement includes J&J pleading guilty to a criminal misdemeanor for its role in promoting the drug to those groups (United States of America v. Janssen Pharmaceuticals, Inc.; 13-605; U.S. District Court for the Eastern District of Pennsylvania).

Risperdal has been shown to nearly double the risk of heart disease and pneumonia in elderly dementia patients, according to the U.S. Food and Drug Administration.**

“Unfortunately, that $2.2 billion represents criminal and civil fines, not money to compensate victims,” said Rochelle Rottenstein, principal of the Rottenstein Law Group LLP. “Those injured by Johnson & Johnson’s actions should consider retaining an attorney to assist them in seeking to obtain compensation for harms allegedly suffered from use of the drug."

The Rottenstein Law Group LLP encourages those who believe they or their loved ones have suffered from the alleged side effects of Risperdal to visit the firm's website to learn more about Risperdal lawsuits and side effects.

*nytimes.com/2013/11/05/business/johnson-johnson-to-settle-risperdal-improper-marketing-case.html

**http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm152291.htm
About THE ROTTENSTEIN LAW GROUP LLP
The Rottenstein Law Group LLP is a New York-based firm that represents clients nationwide in mass tort actions. The firm was founded by Rochelle Rottenstein, who has more than two decades of experience as a lawyer, to represent clients hurt by defective medical devices and medications. (Attorney advertising. Prior results do not guarantee a similar outcome.)

Contact:
The Rottenstein Law Group LLP
Rochelle Rottenstein, Esq.
321 W. 44th Street
# 804
New York NY 10036
(212) 933-9500 (office phone)
(212) 933-9980 (facsimile)
rochelle (at) rotlaw (dot) com
plus.google.com/106070664376281033016

Read the full story at http://www.prweb.com/releases/risperdal-lawsuits/heart-failure/prweb11315249.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. J&J to Pay $2.2B to Settle Allegations Over Its Marketing of Risperdal; Parker Waichman LLP Applauds Efforts of Whistleblowers in Helping Compel Resolution
2. Risperdal Lawsuit News: Johnson & Johnson To Pay Over $2.2 Billion In Risperdal and Invega Settlement Draws Comment From Wright & Schulte LLC
3. Risperdal Lawsuits: $2.2 Billion Settlement Between Federal Government, Johnson & Johnson Over Alleged Illegal Marketing of Risperdal, Other Medications
4. Risperdal Lawsuit News: Bernstein Liebhard LLP Comments on Settlement in Risperdal Marketing Investigation
5. New Risperdal Lawsuit Filed in Pennsylvania Litigation; Alleges Male Breast Growth Injuries Caused by Anti-Psychotic Medication, Bernstein Liebhard LLP Reports
6. Bernstein Liebhard LLP Investigating Risperdal Lawsuits on Behalf of Victims of Male Breast Growth Allegedly Caused by Risperdal
7. The Consumer Justice Foundation Launches RisperdalLaw.com, an Informational Web Site Dealing with Alleged Risperdal Side Effects Including Gynecomastia
8. Parker Waichman LLP Commends Arkansas Attorney General for Backing Fine Against Johnson & Johnson over Risperdal Off-Label Marketing Allegations
9. Transvaginal Mesh Lawsuit News: Bernstein Liebhard LLP Notes Issuance of New Orders in Federal Litigations for Ethicon, American Medical Systems Lawsuits
10. Stryker Hip Lawsuit News: Bernstein Liebhard LLP Notes Hearing Scheduled on Remand of Stryker Hip Recall Claim to State Court
11. A Consumer Class Action Lawsuit Has Been Filed Over Allegedly Deceptive “Novarel Slim iPant,” “Flexees” Fat Destruction and Cellulite Slimming Claims
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... Viejo, California (PRWEB) , ... June 26, 2016 , ... ... Final Cut Pro X. , "Film editors can give their videos a whole new ... said Christina Austin - CEO of Pixel Film Studios. , ProSlice Levels contains ...
(Date:6/26/2016)... Clarkston, Michigan (PRWEB) , ... June 26, 2016 ... ... respect to fertility once they have been diagnosed with endometriosis. These women need ... but they also require a comprehensive approach that can help for preservation of ...
(Date:6/25/2016)... ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due ... up a new, often overlooked aspect of head lice: the parasite’s ability to live away ... a common occurrence, but a necessary one in the event that lice have simply gotten ...
(Date:6/25/2016)... ... 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned ... the David Geffen School of Medicine at UCLA. He trained in Internal Medicine at ... fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity ...
(Date:6/25/2016)... ... ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter of ... too high can result in disappointment, perhaps even self-loathing. However, those who set the ... Research from PsychTests.com reveals that behind the tendency to set low expectations ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Research and Markets has announced the ... report to their offering. ... favourable commercial environment for MedImmune to enter. The US ageing ... serve to drive considerable growth for effective anti-influenza medications. The ... sales considerably, but development is still in its infancy. ...
(Date:6/23/2016)... -- , , , WHEN: , ... , , , LOCATION: , , , Online, with free ... EXPERT PANELISTS:  , , , Frost & Sullivan,s Global Vice President ... Industry Analyst, Divyaa Ravishankar and Unmesh Lal, Program Manager , ... is witnessing an exceptional era. Several new demand spaces, such as ...
(Date:6/23/2016)... announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered in Bogota. Colombia ... ... ... ... Astellas is a pharmaceutical ...
Breaking Medicine Technology: